Showing results (251-260 of 266) with videos related to
Sort By:
Pageof 27
Clinical and Experimental Dermatology|June 11, 2025
Effectiveness and Safety of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis and Previous Failures of Th2 Biologics: A Propensity Score-Matched StudyFrancesca Barei, Alessandra Chiei-Gallo, Alessandra Narcisi, et al.The Journal of Dermatological Treatment|May 7, 2024
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, et al.Journal of the National Cancer Institute|March 14, 2019
Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 CentersClio Dessinioti, Niki Dimou, Alan C Geller, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 29, 2024
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort studyGianluca Avallone, Francesco Cavallo, Annalisa Tancredi, et al.Clinical and Experimental Dermatology|July 15, 2025
Therapeutic Outcomes Across JAK Inhibitors in Prurigo NodularisGianluca Avallone, Andrea Bombelli, Luca Valtellini, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2020
Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive NomogramAndrea Maurichi, Rosalba Miceli, Hanna Eriksson, et al.Dermatology and Therapy|October 10, 2025
Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort StudyGianluca Avallone, Andrea Bombelli, Luigi Gargiulo, et al.Clinical and Experimental Dermatology|July 9, 2026
Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter StudyMaddalena Napolitano, Giuseppe Lauletta, Marianna Cimmino, et al.International Journal of Dermatology|August 21, 2025
Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective StudyLuca Potestio, Cataldo Patruno, Marika Del Gaudio, et al.Clinical and Experimental Dermatology|June 11, 2024
Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patientsSilvia Ferrucci, Simona Tavecchio, Carlo Alberto Maronese, et al.Pageof 27